Introduction
Glomerulonephropathy (GN) often manifests as proteinuria and progresses to chronic renal failure in many cases [1, 2] . The etiology and pathophysiology of idiopathic GN are yet to be Mesenchymal Stem Cells Ameliorate Adriamycin Induced Proteinuric Nephropathy elucidated in most cases, so specific treatment leading to a cure is not readily available. Instead, non-specific immunosuppressive agents are frequently used, often with unsatisfying outcomes and untoward drug toxicity, rendering search for the non-or less-toxic remedy for the condition desirable. In this aspect, mesenchymal stem cell (MSC) can be a candidate for such a less-toxic therapeutic agent.
MSC is an undifferentiated, multipotent adult stem cell of mesodermal origin. It has the capacity to differentiate into various mesodermal cells such as cartilage, bone, adipose tissue and muscle cells. MSC is also known to have therapeutic potential; the cells migrate to the injured tissue such as infarcted myocardium and assist its healing [3, 4] . Another aspect of MSC with therapeutic potential is its non-specific immune modulating effect, possibly though immunosuppressive cytokine production or induction of immune-modulating cells [5] [6] [7] [8] . The therapeutic potential of MSC has also been documented in kidney injuries; administration of MSC to experimental models of acute renal injury resulted in homing of these cells to the injured kidneys and amelioration of the clinical manifestations of renal injury, through differentiating into renal tubular epithelial cell and/ or paracrine mechanism [9] [10] [11] .
Regarding GN, recent studies using the antiThy1. 1 . model of GN demonstrated that intrarenal injection of MSC at the time of insult accelerated the glomerular healing [12, 13] .
These studies showed the potential of MSC as a therapeutic agent for GN, at least at the acute stage. However, in addition to the concerns of its long-term safety, MSC needs to be tested in a more clinically relevant setting; what would happen if MSCs were administered intravenously, rather than via intra-renal or intracardiac route? What would happen if MSCs were administered to a host suffering from fullblown proteinuric nephropathy, rather than at the time of introduction of insult? In another study using Adriamycin (ADR) to induce nephrosis in rats [14] , only when MSCs were given concomitantly to ADR, which is also a less feasible condition clinically, these cells showed protective effect. In the present study, we tested the therapeutic potential of MSC administered via intravenous route at the time of clinically evident proteinuria. For proteinuric GN induction, we used a well-known murine model of ADR induced proteinuric nephropathy (ADR-GN). ADR exerts a toxic effect on the kidney and induces inflammation, which in turn injure the glomeruli of the kidney [15] [16] [17] .
Materials and Methods

Isolation and Purification of MSC
MSCs were isolated from bone marrow of 8 week-old male Balb/C mice by their tendency to adhere tightly to plastic culture dishes as described previously [18] . Their mesenchymal potential to differentiate toward osteocyte or adipocytes was verified by incubating the cells in differentiation-inducing media as described previously [19] . Differentiation to osteocyte was confirmed by staining calcium-rich hydroxyapatite in the extracellular matrix using Alizarin Red S (Sigma-Aldrich Korea, Yongincity, Korea). Adipogenic differentiation was confirmed by the presence of highly refractive intracellular lipid vacuoles stained with Oil Red O (Sigma-Aldrich Korea, Yongin-city, Korea) [19] .
Murine Model of GN (ADR-GN)
Female Balb/C mice of 8 weeks of age were purchased from the Orient (Seoul, Korea) and 
Monitoring the clinical findings of ADR-GN
Urine samples were collected at 0, 2, 4, 6
weeks after GN induction for urine protein/ creatinine ratio (uPr/Cr) measurement. At 6 weeks after GN induction, the mice were anesthetized with ether, blood samples for blood urea nitrogen (BUN), Cr, total protein, albumin determination were collected, and both kidneys were rapidly removed after perfusion with icecold phosphate-buffered saline using cardiac catheterization.
For the histological examination, tissues were fixed in 10% formalin and embedded in paraffin. Sections (4-m) were stained with μ H&E staining and the degree of glomerulopathy was scored semi-quantitatively as described previously [21] . The degree of mesangial mat- 
Effect of MSC on inflammation
To explore the effect of MSC on immunologi-cal factors, which had been claimed to cause the glomerular injury in ADR-GN [15] [16] [17] 
Statistical analysis
The results are expressed as means± MSCs to produce extracellular matrix with mineral deposition (Fig. 1B) , and adipogenic condition induced the cells to accumulate lipid vacuoles (Fig. 1D) . (Fig. 3) . Although the Kaplan-Meier model of statistical analysis did not reveal statistically significant differences, such favorable survival of the MSC group was also observed in preliminary studies using different dosages of ADR (data not shown). Fig. 2 . MSCs ameliorate adriamycin induced proteinuria. In two weeks of injection, adriamycin induced severe proteinuria in Balb/c mice. Two weeks after the MSC or saline injection, the amount of proteinuria was still significantly higher than that of baseline in the Saline group (P =0.011), but the amount of proteinuria in the MSC group was not different from that of baseline (P >0.05).
MSCs modulate cytokine production in the inflammatory milieu
In ADR-GN, the glomerular injury by ADR is thought to be caused by immune factors as well as direct toxic effect of the drug on the glomerular cells [15] [16] [17] . Since in the present study MSC was administered at the later stage of ADR-GN when proteinuria was evident and the toxicity of ADR was not expected to linger, we sought to explore the effect of MSC on the immunological factors using MLC, an in vitro model of inflammation, which does not require additional chemicals to induce immunological activation. When MSC was added to MLC, the cytokine concentration in the supernatant was affected by MSC (Fig. 4A) . While IFN-, the γ well-known pro-inflammatory cytokine, was decreased, IL-10, the well-known anti-inflammatory cytokine, was increased in the supernatant of MLC when MSC was added to the culture (Fig. 4B ).
Discussion
The purpose of this study was to test the therapeutic potential of MSC that was admini- 3 . Administration of MSC favors survival in ADR-GN mice. At 6 weeks after ADR-GN induction, the survival rate of the Saline group was 77% (n=10) while 90% of the mice in the MSC group (n=10) survived. Fig. 4 . MSCs modulate cytokine production in the inflammatory milieu. When MSC was added to MLC, IFN-, the well-known pro-inflammatory cytokine, γ was decreased (A) and IL-10, the well-known anti-inflammatory cytokine, was increased in the supernatant of MLC when MSC was added to the culture (B). Then, by which mechanism did MSC exert such an effect on the proteinuric nephropathy?
Among the known therapeutic potentials of MSC, the early effect of MSC on acute renal injury is considered to be the paracrine or autocrine effect of MSC rather than the replacement of damaged cellular component of the kidney by differentiating into renal cellular components [10, 11, 26] . By the same token, we speculate that non-specific immune modulating effect of MSC might have worked in this model, through modulating cytokine production in the inflammatory milieu as shown previously [5] .
Although the milieu 2 weeks after ADR injection, when the toxicity of ADR had already disappeared, was impossible to reproduce in vitro, we could verify that the MSC we used in this study had such an immune modulating effect (Fig. 4) . Another possibility is that MSC secreted some factors accelerating the recovery of podocytes or other components of the kidney as shown previously [14] . Or, considering the favorable survival in the MSC group, MSC may have beneficial effect on the cardiovascularhemodynamic system, manifesting less proteinuria in ADR-GN. Further study of pathologic evaluation at different time points might reveal better explanation, especially since a previous study did not show the potential of MSC to modify the clinical parameters in ADR model of rats when administered at different scheme [14] .
Another important issue regarding MSC as a therapeutic agent is its safety concern. Since MSC has multipotency and the capacity of self renewal similar to that of malignant cells, safety concern has constantly been addressed. True to the concern, in previous study by Kunter et al. some of the intra-renally introduced MSC into anti-Thy1.1. GN differentiated into intraglomerular adipocytes 60 days later [13] . On the other hand, such a mal-differentiation was not demonstrated until 24 days later when these cells were injected via tail vein [25] .
Perhaps intravenous MSC administration al- 
